Beijing Beilu Pharmaceutical
Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride … Read more
Beijing Beilu Pharmaceutical - Asset Resilience Ratio
Beijing Beilu Pharmaceutical (300016) has an Asset Resilience Ratio of 10.67% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how Beijing Beilu Pharmaceutical's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Beijing Beilu Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥343.64 Million | 10.67% |
| Total Liquid Assets | CN¥343.64 Million | 10.67% |
Asset Resilience Insights
- Moderate Liquidity: Beijing Beilu Pharmaceutical has 10.67% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Beijing Beilu Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Beijing Beilu Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Beijing Beilu Pharmaceutical (2005–2024)
The table below shows the annual Asset Resilience Ratio data for Beijing Beilu Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.78% | CN¥350.77 Million | CN¥2.98 Billion | +12.39pp |
| 2023-12-31 | -0.61% | CN¥-17.20 Million | CN¥2.82 Billion | -0.08pp |
| 2022-12-31 | -0.53% | CN¥-14.79 Million | CN¥2.82 Billion | -0.15pp |
| 2021-12-31 | -0.38% | CN¥-11.00 Million | CN¥2.90 Billion | -0.13pp |
| 2020-12-31 | -0.25% | CN¥-7.14 Million | CN¥2.85 Billion | +0.21pp |
| 2019-12-31 | -0.46% | CN¥-7.47 Million | CN¥1.62 Billion | -0.41pp |
| 2018-12-31 | -0.05% | CN¥-666.64K | CN¥1.29 Billion | -5.80pp |
| 2016-12-31 | 5.75% | CN¥55.00 Million | CN¥956.09 Million | +4.63pp |
| 2005-12-31 | 1.13% | CN¥1.21 Million | CN¥107.46 Million | -- |